Kyan is a Singapore-headquartered precision medicine biotechnology company that leverages artificial intelligence and advanced computational modeling to provide personalized treatment solutions for cancer patients. The company's proprietary platform combines machine learning algorithms with clinical data to identify optimal drug combinations and dosing strategies tailored to individual patient profiles.

By analyzing tumor genetics, patient characteristics, and treatment response patterns, Kyan enables oncologists to make more informed treatment decisions, potentially improving patient outcomes while reducing adverse effects. The company's innovative approach represents a significant advancement in the shift from one-size-fits-all cancer treatment to precision oncology, where therapy is customized based on the specific molecular and genetic characteristics of both the patient and their cancer.